Global Cannabis Valuation Still Demands Cash Proof
Global cannabis equities are not trading on a single legalization thesis. They are trading on a more demanding and increasingly differentiated question: which operating models can convert growth, regulatory optionality and geographic diversification into durable per-share cash economics?
That distinction matters across Canadian, U.S., European, LATAM and APAC listing venues. The tape is showing pockets of high-beta movement, but not broad confidence in the sector’s earnings power. RWB.CN rose 20.00% on Canada and OTC trading, while RVV.V declined 17.86%. CRDL gained 12.50% on U.S. trading, yet European names B8F.DE and SANT.DE each moved lower. In Australia, OPL.AX advanced 9.09%.
Those daily changes are not a valuation framework. They are, however, a reminder that low-priced, thinly traded cannabis and cannabis-adjacent equities can move sharply without resolving the central underwriting question: whether the enterprise can fund its strategy without consuming disproportionate cash or expanding its share count faster than its cash-flow capacity.
The most useful global read-through comes from Tilray Brands’ recent SEC reporting—not because every cannabis issuer shares its model, but because its disclosures make the sector’s valuation tension unusually explicit. Revenue scale, EBITDA progress, international exposure and beverage diversification can all matter. Yet the equity outcome ultimately depends on cash conversion, capital structure and execution.
Thesis: cannabis valuation is shifting from optionality to conversion
The global sector still carries policy optionality. In the U.S., the administrative process around marijuana rescheduling remains relevant to sentiment and the addressable-market debate. In Europe, medical-cannabis development remains an important strategic pathway for companies operating across regulated channels. Canada remains a deep public-equity venue for cannabis companies, while Australian listings offer another route to medical-cannabis and healthcare-oriented exposure. LATAM remains strategically important as a regional market and production discussion, but the current evidence set does not support a company-specific valuation ranking there.
What can be assessed is the discipline investors should apply across these markets. A company can have a strong revenue narrative and still deliver weak equity economics if it cannot translate adjusted earnings measures into free cash flow. Likewise, a company can be exposed to favorable regulation and still face a valuation ceiling if dilution, debt service, working-capital needs or acquisition integration absorb the operating gains.
That is the core lesson in the Tilray Brands fiscal 2026 earnings release filed as SEC Exhibit 99.1. Tilray reported fiscal 2026 net revenue of $915.454 million, adjusted EBITDA of $61.139 million and negative free cash flow of $98.624 million. For fiscal 2027, management guided to adjusted EBITDA of $68 million to $75 million and stated it expects annual revenue above $1 billion.
The valuation point is not that EBITDA guidance lacks value. It is that EBITDA must be treated as an intermediate operating metric, not the final evidence of equity value creation. For a global cannabis issuer, the gap between adjusted EBITDA and free cash flow can reflect acquisition costs, integration requirements, financing burdens, working capital and capital deployment. Those items are particularly material in a sector where access to conventional capital has historically been uneven and where competitive intensity can pressure both margins and cash conversion.
For global investors, that framework travels. It applies to Canadian small-cap listings, European medical-cannabis platforms, U.S. operators and Australian healthcare-linked cannabis exposures—even though local regulations, currencies, liquidity profiles and investor bases differ.
Tilray’s filings frame the standard for diversified operators
Tilray’s disclosures provide a concrete example of why revenue diversification deserves analysis rather than automatic multiple expansion. The company has cannabis, distribution and beverage operations. Its reported fiscal 2026 results demonstrate operating scale, while its fiscal 2027 guidance implies a further improvement in adjusted EBITDA. But a market participant underwriting the equity still needs a credible bridge from that guidance to free cash flow and per-share economics.
The balance sheet makes this requirement more acute. In the same fiscal 2026 earnings release, Tilray reported $225.977 million of cash and cash equivalents, $5.289 million of marketable securities, $8.775 million of bank indebtedness, $138.585 million of current and long-term debt, and $79.529 million of convertible debentures. It also reported 131,683,075 common shares issued and outstanding at the fiscal year-end, compared with 106,067,875 one year earlier after retrospective adjustment for the reverse split.
That does not establish a per-share valuation conclusion by itself. The available record lacks a verified peer-multiple set, current consensus forecasts, full dilution analysis and a documented segment-level free-cash-flow model. But it does establish the proper analytical order. Investors should first ask whether EBITDA growth can reduce cash consumption; second, whether cash improvement can occur without material dilution; and third, whether diversification produces returns above the cost of capital rather than merely additional revenue.
Tilray’s beverage strategy is central to that test. The company described BrewDog as a fiscal 2026 acquisition supporting a pro forma global beverage platform of approximately $500 million. An earlier disclosure described an acquisition price of approximately £40 million in cash and a Carlsberg partnership beginning in 2027. The relevant Tilray Brands fiscal 2026 and third-quarter earnings release is therefore not simply an M&A document; it is a valuation document. The strategic value of beverage diversification will depend on disclosed profitability, cash-flow progression and integration execution—not on platform scale alone.
Canada, Europe and APAC: different venues, same valuation discipline
Canada’s cannabis market remains central to public-market price discovery, but recent trading illustrates the difference between momentum and fundamental rerating. RWB.CN closed at $0.03, up $0.01, or 20.00%, on volume of 4,000. CIN continues to classify the company as distressed. That status matters more than the one-session percentage move. At this end of the market, price action can be highly sensitive to liquidity and positioning; a large percentage move from a small absolute price base is not evidence of a repaired balance sheet or a validated cash-flow inflection.
The opposite move carries the same lesson. RVV.V traded at $0.02, down $0.01, or 17.86%, on volume of 26,006, and also remains on CIN’s distressed list. The difference between RWB.CN and RVV.V is a useful reminder that binary daily moves are not a substitute for a capital-structure view. Investors seeking Canadian exposure should distinguish between equity optionality and operating evidence, especially where public information does not support a comprehensive valuation model.
CRDL adds another Canadian-listed reference point. Its U.S.-listed shares traded at $1.71, up $0.19, or 12.50%, on volume of 2,121,371; its Canadian listing, CRDL.TO, gained 14.15% on volume of 360,761. The cross-listed move underscores that liquidity can concentrate around a single issuer even when the broader cannabis tape is fragmented. But volume alone should not be mistaken for a valuation catalyst. Without a filing-led change in cash runway, commercialization assumptions, profitability or capital needs, price momentum remains a sentiment signal rather than an earnings revision.
Europe presents a different regulatory and market-structure profile, but it does not eliminate the same valuation requirements. B8F.DE, associated with Cantourage, declined 1.7%. SANT.DE, associated with SynBiotic, fell 0.8% and remains on CIN’s distressed list. European operators may offer differentiated exposure to medical-market development and cross-border regulatory structures, but their listed equity value still turns on disclosure quality, liquidity, financing access and the ability to establish repeatable economics under local rules.
Australia offers another differentiated venue. OPL.AX traded at $0.01, up 9.09%. That move should be read carefully. APAC-listed cannabis exposure can respond to local risk appetite and healthcare-sector positioning, but the same global financing reality applies: when capital becomes selective, investors tend to prioritize balance-sheet resilience and visible cash conversion over distant addressable-market claims.
Policy optionality remains real, but timing is not valuation
The U.S. regulatory calendar is a legitimate cross-border sentiment driver. The DEA marijuana-rescheduling hearing occurred from June 29 through July 15, and the administrative law judge set August 17 as the deadline for proposed transcript corrections and post-hearing briefs, according to the DEA order for transcript corrections and post-hearing briefs.
That timetable matters for global cannabis equities because U.S. policy developments can affect sector-wide risk appetite, even for Canadian, European and Australian listings. But timing remains unresolved, and the available record does not establish a final agency outcome. Investors should therefore resist attaching a definitive valuation uplift to a procedural milestone.
The differentiated impact could be meaningful. U.S.-linked cannabis valuations are typically more directly sensitive to federal-policy developments. Canadian LPs may receive a sentiment read-through, but their value depends on their own international, medical, beverage, consumer or distribution strategies. European and APAC operators may be less directly exposed to U.S. policy, but they are not insulated from shifts in global cannabis capital flows and investor appetite.
Macro, liquidity and the global cost of risk
No macro data are available in the current package, which is itself important for valuation discipline. Without verified evidence on rates, the U.S. dollar or broader risk appetite, investors should not force a macro conclusion into a company-level model.
The appropriate qualitative framework is straightforward. A stronger preference for risk assets can support liquidity and speculative participation in smaller cannabis listings across Canada, Europe and Australia. A more restrictive financing environment can have the opposite effect, particularly for issuers that require external capital before free cash flow is established. Currency and listing venue can change the path, but not the destination: the cost and availability of capital feed directly into dilution risk and therefore into per-share valuation.
Tilray’s fiscal 2026 Form 10-K explicitly identifies significant competition across cannabis and beverage operations, including illicit-market participants and large, well-capitalized competitors. The fiscal 2026 Form 10-K reinforces a sector-wide principle: valuation should not rely on regulatory access alone when competition can limit margins and cash conversion.
Bottom line
The global cannabis valuation debate is becoming less about who has the broadest narrative and more about who can demonstrate a credible progression from revenue to adjusted EBITDA to free cash flow—without disproportionate dilution.
The concrete benchmark is Tilray’s fiscal 2027 adjusted EBITDA guidance of $68 million to $75 million against fiscal 2026 negative free cash flow of $98.624 million. That spread captures the sector’s central challenge. Revenue growth and strategic diversification can create upside optionality, but the market needs proof that those initiatives improve per-share cash economics.
What we’d watch: disclosed free-cash-flow improvement, changes in share count, debt and convertible obligations, and evidence that acquisition-led platforms generate measurable profitability. Across Canadian names such as RWB.CN, RVV.V and CRDL, European names such as B8F.DE and SANT.DE, and APAC exposure through OPL.AX, we would lean toward treating sharp daily price moves as liquidity and sentiment signals until filings demonstrate durable cash conversion.